Joshua Hexter Biography and Net Worth

Joshua Hexter is the COO of Oramed Pharmaceuticals. They are 56 years old.

What is Joshua Hexter's net worth?: The estimated net worth of Joshua Hexter is at least $4.26 million as of July 1st, 2026. Hexter owns 1,023,384 shares of Oramed Pharmaceuticals stock worth more than $4,257,277 as of July 27th. This net worth evaluation does not reflect any other investments that Hexter may own. Learn More about Joshua Hexter's net worth.
How do I contact Joshua Hexter?: The corporate mailing address for Hexter and other Oramed Pharmaceuticals executives is 1185 AVENUE SUITE 228, NEW YORK NY, 10036. Oramed Pharmaceuticals can also be reached via phone at (844) 967-2633 and via email at [email protected]. Learn More on Joshua Hexter's contact information.
Has Joshua Hexter been buying or selling shares of Oramed Pharmaceuticals?: In the last ninety days, Joshua Hexter has sold $611,020.00 of Oramed Pharmaceuticals stock. Most recently, Joshua Hexter sold 137,000 shares of the business's stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $4.46, for a transaction totalling $611,020.00. Following the completion of the sale, the chief operating officer now directly owns 1,023,384 shares of the company's stock, valued at $4,564,292.64. Learn More on Joshua Hexter's trading history.
Who are Oramed Pharmaceuticals' active insiders?: Oramed Pharmaceuticals' insider roster includes Avraham Gabay (CFO), Joshua Hexter (COO), Nadav Kidron (CEO), and Kevin Rakin (Director). Learn More on Oramed Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Oramed Pharmaceuticals?: During the last year, insiders at the biotechnology company sold shares 2 times. They sold a total of 210,360 shares worth more than $941,873.60. The most recent insider tranaction occured on July, 1st when COO Joshua Hexter sold 137,000 shares worth more than $611,020.00. Insiders at Oramed Pharmaceuticals own 17.8% of the company. Learn More about insider trades at Oramed Pharmaceuticals.
Information on this page was last updated on 7/1/2026.

Joshua Hexter Insider Trading History at Oramed Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/1/2026	Sell	137,000	$4.46	$611,020.00	1,023,384

Joshua Hexter Buying and Selling Activity at Oramed Pharmaceuticals

Oramed Pharmaceuticals Company Overview

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

Today's Range

Now: $4.16

$4.06

$4.17

50 Day Range

MA: $4.10

$3.60

$5.00

2 Week Range

Now: $4.16

$1.98

$5.19

Volume

73,122 shs

Average Volume

235,067 shs

Market Capitalization

$170.27 million

P/E Ratio

1.61

Dividend Yield

6.20%

Beta

1.21